AbbVie seeks lift from 'guided missile' cancer drug with $10 billion ImmunoGen deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Immunogen (IMGN) shares surge on news of takeover by AbbVie (ABBV)
November 30, 2023 9:09 AM ESTAbbVie (NYSE: ABBV) announced Thursday that it will acquire Immunogen (NASDAQ: IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share.
The transaction values ImmunoGen at a total equity value of approximately $10.1 billion and is expected to close in the middle of 2024.
Elahere... More
